Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Ariad Faces Court Reversal in Eli Lilly Dispute

By Pharmaceutical Processing | April 6, 2009

CAMBRIDGE, Mass. (AP) — Ariad Pharmaceuticals Inc. said Friday an appeals court reversed a ruling in the company’s patent lawsuit claiming Eli Lilly and Co. products infringed on the company’s technology. In 2006, a U.S. District Court jury in Boston awarded Ariad and three co-plaintiffs about $62.5 million. Ariad and its partners accused El Lilly of infringing a patent that covers any medical treatment targeting the body’s molecular pathway called NF-kappa B. The specific Eli Lilly drugs at issue included the osteoporosis drug Evista and sepsis treatment Xigris. On Friday, the U.S. Court of Appeals for the Federal Circuit reversed that decision, saying that four of the patent claims used to support Ariad’s case were invalid because of inadequate written description. Ariad said the court did not rule on other validity issues by Eli Lilly. “While we are disappointed by the Appeals Court’s ruling, the decision involves only one of the technical requirements for validity and focuses solely on the four asserted claims,” said Ariad Chairman and Chief Executive Dr. Harvey J. Berger, in a statement. “We believe that this decision may allow us to pursue further legal action and judicial review of the ruling.” Eli Lilly representatives said they were pleased with the ruling because they believe the decision applied long-standing patent law principles. “Over many years the court’s rulings have provided effective protection for biotechnology inventions while rejecting attempts at claims extending beyond the inventor’s work,” said Robert A. Armitage, senior vice president and general counsel for Lilly, in a statement. Evista is one of Eli Lilly’s best-selling drugs, with sales of just under $1.08 billion in 2008.

Related Articles Read More >

Doctor, woman patient and tablet for consulting with results, medical info and talk for healthcare with mockup space. Japanese medic, digital touchscreen or show video for surgery, wellness or advice.
Putting patients first in clinical trials
Confidently navigate the transition from bench to batch
Merck
FDA approves Merck’s Winrevair to treat pulmonary arterial hypertension
kobayashi pharmaceutical logo
Report: Japan health authorities investigate Kobayashi Pharmaceutical factory after five deaths
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE